Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2019
Price : $35 *
At a glance
- Drugs Anakinra (Primary)
- Indications Febrile neutropenia; Mucositis
- Focus Adverse reactions
- Acronyms AFFECT-1
- 13 Jun 2019 Planned End Date changed from 1 Nov 2019 to 1 Jun 2020.
- 13 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 03 May 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2019.